A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
about
Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methodsSurveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention.Signal detection based on time-to-onset: extending a new method from spontaneous reports to observational studies.Near real-time vaccine safety surveillance with partially accrued data.Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual.Signal detection and monitoring based on longitudinal healthcare dataA modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.Likelihood ratio based tests for longitudinal drug safety data.Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System.Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.The upper bound to the Relative Reporting Ratio-a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection.Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.A critical review of methods to evaluate the impact of FDA regulatory actions.Composite sequential Monte Carlo test for post-market vaccine safety surveillance.Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink's Rapid Cycle Analysis Capabilities.Methods for observational post-licensure medical product safety surveillance.The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.Decision-making theories: linking the disparate research areas of individual and collective cognition.Methods for safety signal detection in healthcare databases: a literature review.Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study.Quantifying the impact of time-varying baseline risk adjustment in the self-controlled risk interval design.Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety.Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.An event-based approach for comparing the performance of methods for prospective medical product monitoring.Continuous sequential boundaries for vaccine safety surveillance.Disproportionality methods for pharmacovigilance in longitudinal observational databases.Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.Impact of exposure accrual on sequential postmarket evaluations: a simulation study.Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network.Do delays in data availability limit the implementation of near real-time vaccine safety surveillance using the Clinical Practice Research Datalink?Assessing performance of sequential analysis methods for active drug safety surveillance using observational data.Type I error probability spending for post-market drug and vaccine safety surveillance with binomial data.Sequential Statistical Methods for Prospective Postmarketing Safety SurveillanceA Propensity Score-Enhanced Sequential Analytic Method for Comparative Drug Safety Surveillance
P2860
Q28075754-2A0F29C6-087B-469A-B4F7-4F50AEA807E8Q30249793-F72B4940-2571-4E29-A740-5D13E648C50FQ30363763-6045001A-1C4E-4814-AD35-10A469237CB3Q30402264-795FDF8C-9A53-4776-97CE-CAF5B463F731Q30588232-1211BBE8-BAFB-47D7-866C-A4D4C71CB561Q30706851-C9303E3A-5251-4CC3-B69E-61377232480AQ30812957-23B7988E-1205-44DD-93C6-E8E3C9F7CA80Q30830496-6F9AC5DB-0F40-4887-AF5E-184BDC3DDF3DQ31024252-7B29AA28-9FA3-4335-ACAB-50CF6558AEFBQ34133842-63D11B51-5BB9-42C2-83F0-DBD8B94B05DCQ34133849-43C8A2EF-5B9F-448B-8958-DA320D68EC7DQ34133971-31F3F348-32B3-43AA-ABD8-E8CEF606FA30Q34226785-20091ADD-037B-409F-A49B-52CA204905BBQ34699150-ECC65BC9-8F02-4838-8781-DE7F109B3006Q36955813-031DFB2B-51DB-4A87-9348-2FA7AA4CCF83Q37301216-5507D9BE-B498-43EC-999E-31673D0F8ADAQ37315456-4DF57FA8-F039-42CF-BD87-4A7FAFC5283BQ37327861-1A37CDAF-DC7E-4895-A1A9-7FCC64CD2A49Q37964440-06A1D1C7-B314-4EB1-B5C9-9F7975E0EAA4Q37977410-FBC5F88A-5C23-41F1-AF6E-9742B7C3530FQ38099254-A1DDA903-5C3C-4B76-B245-41BDAEF525AFQ38793916-B1AA9808-8204-4424-A25F-FA465450791CQ38804897-4EE15710-108E-46CD-8A88-CE3E3E7CEA5EQ40261938-7F7AB3F9-4083-4ADF-965B-CEDA5DAE6CEBQ40435214-C79469E3-01E0-418D-8DF8-EDBA961F713EQ40812015-AD301F5D-8269-4588-AF0A-9C1B02D80D34Q41686667-86AF9D57-8BD5-4D89-8D32-8B04D5497033Q42081471-CC199BB6-C19F-4CAB-B8E8-961483167DA5Q42191568-2127FEFC-6D41-48C2-8031-3D8F1CEB0B55Q42221013-E79BA045-F10C-4776-8570-FA5C7C80F286Q43432728-315E95A1-8E16-40F1-BD77-704FDF29F08FQ44475855-1A68A42F-AE8C-4572-8DAE-512871480B18Q45162452-BA008D4D-A29E-498D-92BD-3E67FE997190Q45733534-E4074B15-2FA9-48FA-8E91-D161F2D5205AQ47369849-AC93D8FF-32AF-433B-9D3D-C370A33DA5F4Q47386237-419AC4F6-1CB4-4AFE-80F5-4314EBF297C0Q47441653-34C70BD4-9E95-42D3-A590-10E7336891BEQ47921487-2F493136-F6D7-413A-B55A-63A576B3C047Q57590034-B2310FEB-40D9-4F1D-A1C9-877B6BC00E27Q57590042-2F503D3F-10E5-47AB-9890-152EF502B88A
P2860
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
@ast
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
@en
type
label
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
@ast
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
@en
prefLabel
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
@ast
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
@en
P2093
P2860
P3181
P1433
P1476
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
@en
P2093
Edwin Lewis
Margarette Kolczak
Richard Platt
Robert L. Davis
Tracy Lieu
P2860
P3181
P356
10.1080/07474946.2011.539924
P577
2011-01-21T00:00:00Z